NCT06613932 Assessment of L-PRF, Nanohydroxyapatite Combined With L-PRF Using Pulpotomy in Mature Mandibular First Molars
| NCT ID | NCT06613932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Future University in Egypt |
| Condition | Irreversible Pulpitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2023-10-30 |
| Primary Completion | 2024-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2023-10-30 with a primary completion date of 2024-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical and Radiographic Assessment of L-PRF, Nanohydroxyapatite material combined with L-PRF scaffold in Vital pulp Therapy. Treatments in Mandibular First Molars with Closed Apices, Randomized Controlled Trial.
Eligibility Criteria
Inclusion criteria: Patients should be free from any systemic disease. Patients of either gender aged from 15-30. Patients will agree to the consent and will commit to a follow-up period. Soft tissues around the tooth are normal with no swelling or sinus tract. The tooth is restorable tooth has signs and symptoms of irreversible pulpitis of the mature root The tooth doesn\'t contain any internal or external resorption or periapical lesions. The tooth should give a positive response to the cold test. Exclusion criteria: Pregnant and lactating females. Patients with Mental disturbance. Patients who could/would not participate in a 6-month follow-up. A tooth with immature roots. Patients with necrotic pulp.• tooth with periapical lesions or infections. Soft tissue having fistula or swelling Homoeostasis after 10 minutes can not be controlled after total pulpotomy
Contact & Investigator
wael K hussein, professor
STUDY DIRECTOR
future
Frequently Asked Questions
Who can join the NCT06613932 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 30 Years, studying Irreversible Pulpitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06613932 currently recruiting?
Yes, NCT06613932 is actively recruiting participants. Contact the research team at nadaaymaan55@gmail.com for enrollment information.
Where is the NCT06613932 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06613932 clinical trial?
NCT06613932 is sponsored by Future University in Egypt. The principal investigator is wael K hussein, professor at future. The trial plans to enroll 45 participants.